Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report), with a price target of $20.00. Jason McCarthy provided a Buy rating on Actinium ...

(RTTNews) - Actinium Pharmaceuticals, Inc. (ATNM) said Tuesday that the independent Data Monitoring Committee or DMC has completed the single ad hoc interim analysis of the pivotal Phase 3 SIERRA ...

Researchers grew crystals containing actinium and illuminated them with X-rays to learn how the radioactive metal binds with other elements. That information could help design better cancer treatments ...

Actinium Pharmaceuticals Inc (AMEX:ATNM) shares are trading higher Tuesday after the company announced full data results from the pivotal Phase 3 SIERRA trial in patients with active, relapsed or ...

Actinium's SIERRA did not meet secondary endpoint of overall survival on an intent-to-treat basis analysis due to the high crossover rate. Upon concluding its interactions with the FDA, Actinium will ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Actinium Pharmaceuticals (ATNM) is a stock that can certainly ...

Andes Seth, Actinium's Chairman and CEO, stated, "Through her career, June has amassed significant experience in translational research, drug development and business development that has resulted in ...

Metastatic castration-resistant prostate cancer (mCRPC) is a severe form of late-stage disease where the tumor can no longer be controlled with hormone therapy. Even in such situations, effective ...

Actinium gains business development and investor relations expertise as well, as the Company raises its profile in the investment community. These four hires bring to the Company a robust and ...

Actinium Pharmaceuticals (NYSE:ATNM) traded higher on Tuesday as H.C. Wainwright highlighted its buyout potential after its peer in the radiopharma space, Fusion Pharma (FUSN), agreed to be acquired ...